Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.



Enzo Biochem, Inc. (NYSE:ENZ) reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations. Total revenues for the first quarter of fiscal 2011 increased to $25.7 million, from $25.2 million a year ago, or 2%, despite slightly lower revenues at Life Sciences resulting from a program to emphasize higher margined products, and advanced 3% sequentially. Enzo Clinical Labs benefited from an increase in market share and a new provider contract.

Gross profit margin improved 17% to $13.5 million, or 53% of revenues, compared to the fiscal 2010 fourth quarter’s $11.5 million and was a slight improvement year over year. R&D expenses were $1.8 million, 28% lower than both a year ago and in the July 2010 quarter, and SG&A declined $0.5 million to $11.0 million, as a percentage of revenues down 3% from a year ago and 1% from the prior quarter. Overall operating expenses, including R&D, SG&A, legal and provision for uncollectible accounts were $14.6 million, a decline of 4% from last year’s first quarter and 7% from the preceding July period. The operating loss decreased 42%, to ($1.1) million from the corresponding year-ago period, while the net loss of ($1.1) million was 38% lower year over year. EBITDA, adjusted for approximately $1.1 million in both periods for depreciation and amortization, was $23,000, compared to a year ago EBITDA loss of ($959,000), an improvement of $936,000.

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including esoteric tests, to the medical community. Since Enzo Biochem’s founding in 1976, Enzo Biochem’s strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Biochem has three divisions: Life Sciences, Clinical Labs, and Therapeutics. In the course of Enzo Biochem’s research and development activities, Enzo has also developed a substantial portfolio of intellectual property asset with patent coverage across a number of key technologies


Crown Equity Holdings Inc. (OTCBB:CRWE) revealed that its subsidiary company, Crown Tele Services Inc. is still moving forward after dissolving its joint venture with Communication Expert Corporation and will gradually start rolling out its internet based voice and video service IP-PBX solutions next year. The cornerstone of Crown Tele Services Inc. strategy is to meet the highest standards when it comes to delivering VoIP (Voice over Internet Protocol) communication solutions specifically designed to meet the market needs.

According to ABI Research, the latest global business VoIP services forecasts show that the value of the overall market, which includes VoIP integrated access, SIP trunking, hosted IP-PBX/IP Centrex and managed IP-PBX services, is set to double over the next five years, to exceed $20 billion by 2015. Hosted IP-PBX is often a superior alternative that any others based IP PBX system. It provides a effective set of business-grade calling features and combines all your local, telephone long distance and access to the internet services spanning a single network connection. This way, it is possible to benefit from all the calling features from any location.

Crown Equity Holdings Inc., together with its digital network, currently provides electronic media services specializing in online publishing and Web sites, which bring together targeted audiences and advertisers that want to reach them. Crown Equity Holdings Inc. offers internet media-driven advertising services, which covers and connects a range of marketing specialties, as well as search engine optimization for clients interested in online media awareness. Crown Equity Holdings Inc. announced in June of this year its 1- 10 forward stock split, as well as in August announcing that the company had surpassed One Million dollars (1,000,000) in sales.


Cresud Inc. (Nasdaq:CRESY) announced it has filed its annual report on Form 20-F, including its audited financial statements for the fiscal year ended June 30, 2010, with the U.S. Securities and Exchange Commission (the "SEC") in accordance with United States requirements. Cresud's Form 20-F can be accessed on the Investor Relations section of the Company's website at, as well as on the SEC's website at Interested parties may also request a hard copy of the filing free of charge by contacting IR department at

Cresud, Inc., through its investment in BrasilAgro-Companhia Brasileira de Propriedades Agricola, engages in the production of basic agricultural commodities primarily in Brazil and other Latin American countries.


Aruba Networks, Inc. (Nasdaq:ARUN) announced that it has completed its purchase of Sydney, Australia-based Amigopod‘s assets and technology, including its leading network authentication solutions, that allow businesses to provide time- and policy-bound network access to visitors, contractors and employees. The Amigopod solution scales to satisfy the needs of large enterprise campus networks and multi-site deployments and easily integrates with multi-vendor, multi-technology networks for indoor, outdoor, wired and wireless access.

Aruba Networks, Inc. provides an enterprise mobility solution that enables secure access to data, voice, and video applications across wireless and wireline enterprise networks in the United States and internationally.


Finish Line Inc. (Nasdaq:FINL) reported results for the third quarter of fiscal 2011, representing the 13-week period ended November 27, 2010. Net sales increased 8.7% to $260.9 million in the third quarter compared to $240.1 million one year ago. Comparable store net sales increased 10.1% in the third quarter compared to an increase of 1.7% a year ago. Finish Line reported third quarter income from continuing operations of $4.1 million, or $0.08 per diluted share compared to income from continuing operations of $6.5 million or $0.12 per diluted share a year ago, a figure that included a one-time $6.5 million tax benefit Finish Line recorded in the third quarter of last year.

The Finish Line, Inc., together with its subsidiaries, operates as a mall-based specialty retailer in the United States.

Sign-Up For Free Stock Alerts At

business Card 3


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings, Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings, Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings, Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings, Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.